← Back to headlines
AstraZeneca's Ultomiris Expansion to Grow Rare Disease Portfolio
The potential for AstraZeneca PLC (AZN) to expand its rare disease portfolio through the Ultomiris expansion is being assessed.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
